Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q4 EPS of ($0.17), $0.06 better than the analyst estimate of ($0.23).

For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.